Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.

MLA

Gupta, Pranav, et al. “Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.” Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, vol. 45, no. 4, 2018, pp. 1515–28. EBSCOhost, https://doi.org/10.1159/000487578.

APA

Gupta, P., Zhang, Y.-K., Zhang, X.-Y., Wang, Y.-J., Lu, K. W., Hall, T., Peng, R., Yang, D.-H., Xie, N., & Chen, Z.-S. (2018). Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 45(4), 1515–1528. https://doi.org/10.1159/000487578

Chicago

Gupta, Pranav, Yun-Kai Zhang, Xiao-Yu Zhang, Yi-Jun Wang, Kimberly W Lu, Timothy Hall, Richard Peng, Dong-Hua Yang, Ni Xie, and Zhe-Sheng Chen. 2018. “Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.” Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology 45 (4): 1515–28. doi:10.1159/000487578.